Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

ID#: NCT03781752

Age: 6 - 26 years

Gender: All

Healthy Subjects: No

Study Phase: Phase 4

Recruitment Status: Recruiting

Start Date: March 04, 2018

End Date: July 31, 2023

Contact Information:
Beth Krone, PhD
212-241-8012
John Markowitz, PharmD
Summary: The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Eligibility:

Inclusion Criteria:

- Youth ages 6-26 years with ADHD as a primary diagnosis

- For former participants of MPH trials to be invited back for PK procedures.

Exclusion Criteria:

- Participants that do not have ADHD as a primary diagnosis

- Participants that do not want, require, or are not healthy enough for medication treatment with MPH for ADHD per the clinical judgment of the treating and study clinicians

- Participants that are smokers or, are pregnant